Literature DB >> 3708576

Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

S Shionoya, Y Lu, K J Scanlon.   

Abstract

When K562 cells were made resistant to cisplatin their neutral amino acid transport systems changed. K562 cells cloned in cisplatin developed a 6.7-fold resistance to the drug. The generation times for K562 cells sensitive (S) and resistant (DDP) to cisplatin were similar. The initial uptake and rapid efflux of cisplatin were similar in both cell lines. However, they differed in their sodium dependent neutral amino acid transport properties. In K562S cells the sodium-dependent uptake for methylaminoisobutyric acid was significantly inhibited by threonine (Ki = 10.3 mM), but in K562DDP the uptake of neutral amino acids was significantly lower, and methylaminoisobutyric acid uptake was minimally inhibited by threonine. When K562DDP cells were grown in the absence of cisplatin for 8 weeks, their amino acid transport properties reverted to those of K562S cells. In K562 cells, changes in plasma membrane essential amino acid transport systems were concomitant to both the development of resistance and the redevelopment of sensitivity to cisplatin. Therefore, human malignant cell sensitivity and resistance to cisplatin may be related to membrane nutrient transport systems.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708576

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Authors:  K J Scanlon; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.

Authors:  P J O'Dwyer; M J Cornfeld; R Peter; R L Comis
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Mechanisms of cellular resistance to cisplatin.

Authors:  G A Hospers; N H Mulder; E G De Vries
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 5.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

8.  Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Authors:  J M Onoda; K K Nelson; S M Pilarski; N S White; R G Mihu; K V Honn
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

9.  The role of methionine in methotrexate-sensitive and methotrexate-resistant mouse leukemia L1210 cells.

Authors:  K J Scanlon; M Kashani-Sabet; A R Cashmore; M Pallai; B A Moroson; M Saketos
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Authors:  K J Scanlon; E M Newman; Y Lu; D G Priest
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.